The brassinosteroid receptor brassinosteroid insensitive 1 (BRI1) is a member of the leucine-rich repeat receptor-like kinase family. The intracellular kinase domain of BRI1 is an active kinase and also encapsulates a guanylate cyclase catalytic centre. Using liquid chromatography tandem mass spectrometry, we confirmed that the recombinant cytoplasmic domain of BRI1 generates pmol amounts of cGMP per lg protein with a preference for magnesium over manganese as a co-factor. Importantly, a functional BRI1 kinase is essential for optimal cGMP generation. Therefore, the guanylate cyclase activity of BRI1 is modulated by the kinase while cGMP, the product of the guanylate cyclase, in turn inhibits BRI1 kinase activity. Furthermore, we show using Arabidopsis root cell cultures that cGMP rapidly potentiates phosphorylation of the downstream substrate brassinosteroid signaling kinase 1 (BSK1). Taken together, our results suggest that cGMP acts as a modulator that enhances downstream signaling while dampening signal generation from the receptor.
INTRODUCTION
The plant hormone brassinosteroid controls plant growth and development, and in Arabidopsis is perceived by the leucine-rich repeat receptor kinase brassinosteroid insensitive 1 (BRI1). BRI1 is a single membrane spanning receptor kinase that when bound by the brassinosteroid, brassinolide, induces heterodimerization with BRI1-associated receptor kinase (BAK1)/somatic embryogenesis receptorlike kinase 3 (SERK3). This association brings the cytoplasmic C-termini of both molecules into close proximity (Clouse, 2011; Hothorn et al., 2011; Sun et al., 2013) allowing for auto and trans-phosphorylation of both BRI1 and BAK1 and the subsequent phosphorylation of the downstream targets BRI1 substrate kinases (BSKs) (Tang et al., 2008; Sreeramulu et al., 2013) and constitutive differential growth 1 (CDG1) (Kim et al., 2011) that are involved in activating several transcription factors to regulate brassinosteroid dependent gene expression. Although many elements of the brassinosteroid pathway have been extensively studied it remains unclear how the BRI1 kinase domain switches from its inactive basal to its phosphorylation capable activated state, which allows phosphorylation of partners and downstream targets and how it is in turn down-regulated back to the basal state.
Protein regulation is essential in all living organisms to ensure correct spatial and temporal protein expression but also for regulation in response to environmental cues particularly in plants as they are sessile. Recent improvements in imaging resolution have identified restricted localization of signaling molecules within cellular cytoplasmic areas in microdomains or microenvironments such as the Solanum tuberosum sucrose transporter SUT1 (Kr€ ugel et al., 2008) or Medicago truncatula lysine motif receptor like kinase 3 (LYK3; (Haney et al., 2011) . Considering that cellular interiors are crowded with densely packed proteins (Fulton, 1982; Spitzer and Poolman, 2013) , it is only natural that signaling molecules are restricted to microenvironments that contain a complex of scaffold and interacting proteins.
Cyclic GMP (cGMP) is a key signaling intermediate in eukaryotes, including higher plants, in which a diverse group of responses is dependent on cGMP including changes in ion movement, phosphoproteome and transcriptome (Maathuis, 2006; Isner et al., 2012; Facette et al., 2013; Marondedze et al., 2016b) . Using a rationally designed search motif, we identified and experimentally confirmed a number of molecules with guanylate cyclase (GC) activity. Some of these molecules are receptor-like kinases that have the GC catalytic centre embedded within subdomain IX of the kinase domain and in vitro studies have shown that BRI1 (Kwezi et al., 2007) , phytosulfokine receptor 1 (PSKR1) (Kwezi et al., 2011; Muleya et al., 2014) and PePR1 (Qi et al., 2010) all have GC activity. In addition, we have since shown that PSKR1 kinase and GC activity is reciprocally modulated by calcium .
Here we report that the ability of the kinase domain of BRI1 to generate cGMP depends on its kinase catalytic ability. Furthermore, we show that cGMP stimulates phosphorylation of BSK1. Therefore, we propose that cGMP acts as a modulator to stimulate activation of downstream phosphorylation of members of the BRI1 signaling pathway.
RESULTS AND DISCUSSION

BRI1 generates cGMP
Previously, we have shown that a small 114 amino acid fragment of the BRI1 cytoplasmic domain recombinant protein (BRI1 ) has a predicted GC catalytic centre that enabled GC activity ( Figure 1a ). We assessed cGMP generated by the BRI1 1012-1134 using the cGMP enzyme immunoassay assay (EIA) Biotrak system (GE Healthcare, USA) and confirmed this with mass spectrometry (Kwezi et al., 2007) . We later demonstrated that brassinolide induces an increase in cGMP in wild-type freshly isolated protoplasts using the EIA system (Irving et al., 2012) . However, a recent study using a longer portion of the intracellular domain of the recombinant protein (BRI1 ) containing the kinase domain reported that GC activity could not be detected with UV absorbance (Bojar et al., 2014) . As the original construct used was a fragment, it is possible that it could more readily fold as a GC than the longer construct that assumes typical kinase folds crystallised by (Bojar et al., 2014) . In addition, mass spectrometry determination of cGMP is far more sensitive and accurate than either the cGMP enzyme immunoassay assay or the UV detection of HPLC separated fractions (used by Bojar et al., 2014) . In order to address this discrepancy, we undertook liquid chromatography tandem mass spectrometry (LC-MS/MS) to evaluate cGMP production by the cytoplasmic domain recombinant protein, BRI1 (Figure 1b, c) . Similar amounts of cGMP are generated by the recombinant cytoplasmic domain and the full-length PSKR1 (Kwezi et al., 2011; Muleya et al., 2014 Muleya et al., , 2016 . It is noteworthy that a recently characterized adenylate cyclase from Arabidopsis (AtKUP7) also has activity resembling that of plant GCs (Al-Younis et al., 2015) . We therefore conclude that these pmol amount of cyclic nucleotide products per lg recombinant protein determined by the sensitive high resolution mass spectrometry method, is accurate and presumably reflective of physiological conditions. Considering that plant cells have relatively small cytoplasmic interiors, it is only natural that signaling molecules are restricted to microenvironments that contain a complex of scaffold and interacting proteins. Moreover, an Arabidopsis plant natriuretic peptide receptor (AtPNP-A) generates similar amounts of cGMP that in turn affect plant salt and water balance and responses to biotrophic plant pathogens (Turek and Gehring, 2016) indicating that these low amounts of cGMP are physiologically relevant. It was previously reported (Bojar et al., 2014) that no cGMP is produced by the recombinant protein (BRI1 ) when using UV absorbance as a method of detection of cGMP. However, using the far more sensitive tandem mass spectrometry method and microgram amounts of a slightly longer recombinant cytoplasmic domain BRI1
815-
1196 protein we unambiguously demonstrate that cGMP is produced. This difference could be due to the fact that our constructs include the N and C terminal domains necessary for in vitro dimerization as determined by crystallization (Bojar et al., 2014) . Consistent with this consideration, we previously discussed that dimerization is likely to be a prerequisite for guanylate cyclase activity. Soluble monomeric guanylate cyclase subunits are believed to form head-to-tail asymmetric dimers containing metal-binding and transition state-stabilising residues along the intermolecular interface forming the catalytic cleft for GTP binding (Rauch et al., 2008; Winger et al., 2008; Allerston et al., 2013) . Molecular docking of GTP to the GC catalytic centre of the BRI1 GC (Leu 1021 -Arg 1134 ) model reveals the substrate pose and interactions with key residues serine, arginine and aspartic acid of the GC centre (Figure 2a ), which closely resembles that of the PSKR1 GC centre (Wong and Gehring, 2013; Wong et al., 2015) .
Kinase activity is necessary for cGMP production
To investigate if the kinase activity of the protein influences GC activity, we also generated two kinase dead BRI1 mutants; BRI1 815-1196 Y956F and BRI1 815-1196 G989I. BRI1 Y956F simulates the Y956F mutant described by (Oh et al., 2009 ) who showed that this tyrosine residue in subdomain V of the kinase domain and is essential for kinase activity. We show that this Y956F mutation causes a threefold reduction in guanylate cyclase activity to 1.85 AE 0.10 pmol of cGMP per lg protein with a similar preference for magnesium over manganese, 0.30 AE 0.05 pmol of cGMP per lg protein, as co-factor (Figure 1c) . As phenylalanine and tyrosine are about the same size, the reduction in GC activity is therefore attributed to KR1083/4AA and the results are shown in the right panel. cGMP amounts generated by at least two biologically independent clones for each BRI protein were considered. LC-MS/MS was performed in triplicate and the cGMP values were averaged with the error bars representing standard error of the mean. Data were analysed by two-way ANOVA followed by Sidak's multiple comparisons post-hoc test.
the additional reactive hydroxyl group of tyrosine, which allows for interaction with non-protein atoms and importantly for phosphorylation events ( Figure 2b ). We note that the Y956 residue is situated deep into the cavity of the kinase catalytic centre ( Figure 2b ) and importantly, this residue has been previously identified as an auto-phosphorylation site (Oh et al., 2009) . BRI1 815-1196 G989I simulates the bri1-301 mutant isolated by (Xu et al., 2008) . The bri1-301 mutation has a two base alteration from GG to AT which causes glycine 989 to become isoleucine in the kinase domain (within the IVa subdomain) and the mutated plants show moderate morphological phenotypes and a reduced response to brassinosteroids. In vitro assays were used (Xu et al., 2008) to show that bri1-301 has no detectable autophosphorylation activity or phosphorylation activity towards BAK1 or transthyretin-like (TTL). In our hands BRI1 815-1196 G989I also has reduced GC activity, generating only 1.44 AE 0.02 pmol/lg protein and the same preference for magnesium over manganese as the co-factor. When isoleucine takes the place of glycine at position 989, it orientates itself towards an opposing b-sheet causing increased strain with reduced structural flexibility and also increased the overall hydrophobicity in a compact region at the rear of the protein ( Figure 2b ). Such changes may account for the reduced GC activity of the BRI1 815-1196 G989I as structural flexibility in particular is an important feature for multi-functional proteins to allow the switch from one activation state to another as occurs with PSKR1 . Notably wild-type BRI1 has strong autophosphorylation activity resulting in heavily phosphorylated recombinant protein whereas both BRI1 815-1196 Y956F and BRI1 G989I being 'kinase dead' mutants lack phosphorylated residues (Xu et al., 2008; Oh et al., 2009) . Whether the reduction in GC activity observed in the BRI1 mutants is due to lack of kinase activity or lack of phosphorylated residues remains to be investigated. A recent study with recombinant cytoplasmic domain of PSKR1 suggests that the phosphorylation status may be more important as mutations to the kinase active site that inhibited kinase activity did not modulate GC activity (Muleya et al., 2016) .
The GC catalytic centres contain conserved residues involved in selecting specific nucleotides and stabilising the transition state to form the cyclic nucleotide. In BRI1, the GC centre resides in residues 1071-1084 where the glycine at 1073 is predicted to confer substrate selectivity for GTP . Previously, we showed that mutations at position 3 of the GC catalytic centre in the recombinant cytoplasmic domain of PSKR1 resulted in marked changes in cGMP production with a G:K mutation suppressing and G:E mutation enhancing cGMP production (Kwezi et al., 2011; Muleya et al., 2014) . Interestingly, complementation of pskr1/pskr2 null mutant plants with fulllength PSKR1 G923K does not rescue the short root phenotype unlike complementation with wild-type receptor (Ladwig et al., 2015) . We created the BRI1 815-1196 G1073K
and observed that the recombinant BRI1 G1073K shows no change in GC activity and the same preference for magnesium as a co-factor over manganese 7.00 AE 0.43 pmol/lg protein (Mg) and 0.63 AE 0.09 pmol/lg protein (Mn) (Figure 1c) . We observed that in the BRI model incorporating the G1073K mutation, the lysine residue was orientated so that the positively charged side chain is pointing towards the negatively charged phosphates of GTP suggesting stabilising interactions in the presence of the substrate. In addition, there appears to be sufficient space to accommodate the increased bulkiness of lysine orientated in this manner (Figure 2b ). These are possible reasons for why the GC activity of the BRI1 815-1196 G1073K mutant does not alter from the wild-type. Here, we also show in the BRI model that G1073E mutation results in the negative side chain of glutamic acid pointing towards the guanosine of GTP and as there is also sufficient space to accommodate this orientation (Figure 2b ), this change should not negatively affect the GC activity of BRI1. A second mutant in the GC centre BRI1 Figure 1c ). A BRI model incorporating the KR1083/4AA mutations was able to form a helical structural fold (Figure S1 ) that characterizes all Arabidopsis GC centres reported to-date and thus may account for the presence of GC activity albeit at a lowered rate. This observation implied that these positively charged amino acid residues at the GC centre which have been previously identified as key residues for interactions with the phosphate group of the GTP substrate (Wong and Gehring, 2013; Marondedze et al., 2016a) , are required for optimal catalysis.
Modulation of BRI1 kinase activity
As the kinase dead mutants no longer produced cGMP, we also considered the role of the GC centre in modulating kinase activity. To ensure that we were measuring specific BRI1 kinase activity, we used the BR13 peptide as a substrate (Oh et al., 2000) . Recombinant BRI1 wild-type protein effectively phosphorylated the BR13 peptide substrate and as expected the kinase dead BRI1
815-1196 Y956F mutant did not (Figure 3a) . The recombinant BRI1 815-1196 KR1083/4AA, which has reduced GC activity, also consistently showed a reduced ability to phosphorylate the BR13 substrate although it was not significantly different from the wild-type control or the BRI1 815-1196 Y956F mutant ( Figure 3a ). This is similar to PSKR1 in which mutations in the GC catalytic centre in the recombinant cytoplasmic domain that reduce cGMP production do not significantly alter kinase activity although it is reduced . Although both PSKR1 and BRI1 are in the same LRR-Xb family (Shiu et al., 2004) , it is conceivable that the precise interactions between the kinase and GC catalytic centre diverge in the different proteins and that this is dependent upon phosphorylation status. Indeed phosphorylation status of PSKR1 and/or its kinase activity is important in modulating the ability of the recombinant protein to generate cGMP. Mutations in the juxtamembrane position suppressed GC activity despite alternative effects on kinase activity whereas mutations in the active site that abolished kinase activity had no effect on GC activity (Muleya et al., 2016) . We transiently expressed GFP-tagged full-length wild-type BRI1, BRI1Y956F and BRI1KR1083/4AA in tobacco. Full-length GFP-tagged wild-type and mutant proteins were isolated by immunoprecipitation and detected by immunoblot analysis. Immunoprecipitated proteins were incubated with myelin basic protein in the presence of ATP and then separated by SDS-PAGE. Both wild-type and the BRI1KR1083/4AA mutant consistently enhanced phosphorylation of myelin basic protein, whereas phosphorylation was lower with the BRI1Y956F mutant as expected (Figure 3b ). Although the results possibly indicate that BRI1KR1083/4AA has greater kinase activity in planta than in vitro, it should be treated cautiously as different substrates were used in the two assays. So what is the role of cGMP and how does cGMP fit in the broader signaling regulatory mechanisms of BRI1? One possibility is that cGMP is acting as a 'tonic' on the protein and its immediate environs. To test this notion, we determined the effect of cGMP on the kinase activity of wild- ) incorporating the mutations G1073K and G1073E (upper left) were superimposed and they show the orientations of the introduced residues at the GC centre. The models incorporating mutations at G989I (ribbon, lower left) and Y956F (ribbon and surface, upper right) were compared to the non-mutated BR1 815-1196 model. Homology models of BR1 kinase domain (Arg 815 -Leu
1196
) and BRI1 GC centre (Leu 1021 -Arg 1134 ) were based on the crystal structure of the BRI1 kinase domain (PDB entry: 4OA2) which has a sequence similarity of 98% covering 87% of the queried amino acid sequence. Models were built and assessed using Modeller (ver. 9.14) (Sali and Blundell, 1993) and GTP docking simulation was performed using AutoDock Vina (ver. 1.1.2) (Trott and Olson, 2010) . All structures and images were analysed and prepared with UCSF Chimera (Pettersen et al., 2004) and PyMOL (ver. 1.7.4) (The PyMOL Molecular Graphics System, Schr€ odinger, LLC). type BRI1 . We used the Ser/Thr peptide 1 as a substrate and measuring activity with the Omnia kinase assay and show that wild-type BRI1
815-1196 has a K m of~7.5 lM ( Figure S2 ) which is similar to recombinant PSKR1 (Kwezi et al., 2011) using this system albeit lower than that reported for BR13 (Oh et al., 2000) . Interestingly, we observed that the kinase activity of BRI1 815-1196 is suppressed by cGMP (Figure 3c) . A similar effect is seen on the kinase activity of PSKR1 (Kwezi et al., 2011) indicating that cGMP may act to switch down kinase activity in receptor kinase molecules as a type of homeostatic control mechanism. At this stage we can only speculate on the mechanics underpinning the inhibitory effect. One possibility is that a portion of the generated cGMP remains bound (a) Mutations in BRI1 815-1196 affect its ability to phosphorylate the BR13 peptide substrate. The upper panel shows a typical example of BR13 peptide stained by the Pro-Q phosphoblot stain following incubation in the presence or absence of 5 mM ATP and the specified recombinant protein. The lower panel shows the relative change in signal in the presence of ATP correlating to phosphorylation of BR13 peptide. Data were analysed by one-way ANOVA followed by Sidak's posthoc test (*P < 0.05). The error bars represent standard error (SE) from eight to 10 separate assays using at least two independent protein preparations. (b) Transiently expressed GFP-tagged full-length BRI1KR1083/4AA phosphorylates myelin basic protein (MBP). Representative Nicotiana tabacum (Nt) leaf infiltrated with transiently expressed GFP-tagged full-length BRI1 (top left), colour image of GFP expression of the same leaf (top middle left), bright field (top middle right) and GFP filter (top right) of the same leaf. Immunoblot of extracted transiently expressed GFP-tagged full-length BRI1(1), BRI1Y956F (2) or BRI1KR1083/4AA (3) immunoprecipitated from Nicotiana benthamiana (Nb), Nicotiana tabacum (Nt) or Nicotiana glutinosa (Ng) (middle left). Independent Pro-Q Diamond phosphoprotein stained blot of myelin basic protein (MBP) incubated with transiently expressed GFP-tagged full-length BRI1(1), BRI1Y956F (2) or BRI1KR1083/4AA (3) immunoprecipitated from Nicotiana benthamiana (Nb), Nicotiana tabacum (Nt) or Nicotiana glutinosa (Ng) and ATP (bottom left). BRI1 and BRI1KR1083/4AA show increased phosphorylation of MBP compared to MBP alone whereas BRI1Y956F was lower (bottom right). The graph is the average of MBP phosphorylation corrected for average variation in loading derived from GFP immunoblots and error bars represent standard error (SE) from three to five independent leaf infiltrations from three different Nicotiana spp. (c) cGMP suppresses the kinase activity of BRI1 . Recombinant BRI1 815-1196 kinase activity was determined using the Ser/Thr peptide 1 as a substrate and measuring activity with the Omnia kinase assay. Data were analysed by one-way ANOVA followed by Holm-Sidak post-hoc test (**P < 0.01). All experiments were performed in triplicate, and error bars represent SE of a representative experiment from two independent assays. at the GC catalytic centre while BRI1 is in a still active kinase configuration. As more cGMP gets released into the immediate environs, a feedback response occurs where cGMP inhibits the kinase.
cGMP stimulates downstream phosphorylation signals in plant cells
Intracellular changes in cGMP have been associated with activation of ion channels, changes in the transcriptome and phosphorylation of proteins (Maathuis, 2006; Isner et al., 2012; Facette et al., 2013; Marondedze et al., 2016b) . To investigate if cGMP modified any downstream phospho-targets of BRI1, we treated Arabidopsis root cell cultures with 100 nM cGMP for 5 min before extracting all proteins, enriching for phosphopeptides and identifying differentially phosphorylated proteins (Marondedze et al., 2016b) . One of the cGMP-induced phosphoproteins identified was BSK1 phosphorylated on serine 230 (SYpSTNLAYTPPEYLR; Figure 4 ) and threonine 353 (KQEEAPSpTPQRPLSPLGEACSR; Figure S3 ). Previously, BSK1 was identified as a substrate of BRI1 by quantitative proteomics with the major phosphorylated residue being serine 230 (Tang et al., 2008) . Using bifluorescence complementation and co-immunoprecipitation studies Tang et al. (2008) showed that BRI1 and BSK1 interacted in vivo. Following activation of BRI1 via brassinosteroid and dimerization with BAK1, BRI1 phosphorylates BSK1 which then disassociates from the BRI1-BAK1 complex. Previously a phosphopeptide containing phosphorylated threonine 353 was identified in a large-scale screen of Arabidopsis shoots (Reiland et al., 2009) . Although several other proteins were phosphorylated, they could not be statistically correlated due to variability between biological replicates.
Our findings therefore implicate cGMP as an important and previously unidentified component of this signaling cascade. As the production of cGMP is relatively low, its effects are most likely to be evident in the immediate intracellular environment of BRI1 where it is being produced. BSKs are pseudokinases that are thought to act as adaptor or scaffold type proteins as they interact with several proteins in the brassinosteroid pathway such as BRI1 suppressor 1 (BSU1) and brassinosteroid insensitive 2 (BIN2) (Kim et al., 2011; Sreeramulu et al., 2013) as well as FLG2 (Shi et al., 2013) .
The model shown in Figure 5 depicts how BSK1 and cGMP may interact with BRI1 in the inactive and activated states incorporating findings obtained from the literature. In the inactive state in the absence of brassinosteroid, BRI1 forms a complex with BSK1 (Tang et al., 2008; Sreeramulu et al., 2013) and possibly involving BAK1 although this protein may also be interacting with BAK1-interacting receptorlike kinase 2 (BIR2) (Halter et al., 2014) . At this stage, the transcription factors BRASSINOZOLE RESISTANT 1 and 2 (BZR1 and BZR2) will be phosphorylated by BIN2 and this promotes association with 14-3-3 proteins and retention in the cytoplasm (Tang et al., 2008; Clouse, 2011) . The presence of brassinosteroid stimulates oligomerization (if not already occurring) and cross phosphorylation between BRI1 and BAK1 to form a complex (Clouse, 2011) . We speculate that BRI1 in the dimerized state is more likely to generate cGMP (see discussion in regarding PSKR1). Cyclic GMP induces BRI1 to phosphorylate BSK1 (Figure 4 ) which then dissociates from the BRI1-BAK complex. BSK1 can associate with itself and other BSKs to potentially form dimers (Sreeramulu et al., 2013) . Dimerization may be potentiated by BIN2 which can also phosphorylate BSK1 at sites other than serine 230 (Sreeramulu et al., 2013) and the dimer is thought to act as a scaffold for BIN2 and BSU1. Possibly when BSU1 is associated with BSK1 (Kim et al., 2009) , it becomes a substrate for phosphorylation by CDG1 (Kim et al., 2011) and activated. BSU1 is a phosphatase that catalyses the dephosphorylation of the transcription factors BZR1 and BZR2 stimulating dissociation of cytoplasmic complexes and entry into the nucleus and modulation of brassinosteroid dependent gene transcription (Clouse, 2011) . For the sake of simplicity, we have omitted the role of additional transcription factors such as HBI1 that are positively regulated by brassinosteroids but negatively regulated by PAMP-induced immune responses (Malinovsky et al., 2014) as BAK1 has a partly understood role in mediating both growth and immune responses. The cGMP formed by BRI1 also has an inhibitory effect on BRI1 kinase activity and thus acts to dampen the signal networks ( Figure 5 ). Using recombinant cytoplasmic protein, we have shown that BRI1 has both kinase and GC activity and while kinase activity enhances GC activity the product of GC activity, cGMP, supresses the kinase activity of BRI1. Both wild-type and the GC centre mutant full-length proteins expressed in plant tissue also exhibit kinase activity. Furthermore, we have shown that cGMP potentiates phosphorylation of the downstream target BSK1 in cells derived from Arabidopsis roots. The next challenges are to clarify the roles Y956F or G989I play in inhibiting GC activity and to determine residues specific for cGMP binding both in vitro and in planta.
EXPERIMENTAL PROCEDURES Preparation of recombinant protein constructs
Kapa HiFi PCR (KapaBiosystems, Wilmington, MA, USA), oligonucleotides AtBRI1-fwd and AtBRI1-rev (Table S1 ) flanking the BRI1 coding region along with genomic DNA isolated from Arabidopsis thaliana (Col) (Qiagen, Hilden, Germany) were used to amplify the AtBRI1 encoding gene. This PCR product was used as template in another Kapa HiFi PCR with oligonucleotides AtBRI1cd-fwd-gw and AtBRI1-rev-gw-stop or AtBRI1fl-fwd-gw and AtBRI1-rev-gw nostop (Table S1 ) to amplify the respective cytoplasmic or fulllength encoding domain of AtBRI1 (encoding amino acids 815-1196 or 1-1195) incorporating a start codon and Gateway recombination sites. The resulting PCR products were independently recombined into pDONR207 (Invitrogen, Carlsbad, CA, USA) to create pENTRYBRIcds and pENTRYBRIflns which were confirmed through sequencing. BRI1 mutants Y956F, G989I and G1073K were each generated using QuikChange II Site-Directed Mutagenesis kit (Stratagene, San Diego, CA, USA), while the KR1083/4AA mutant was generated using Phusion high-fidelity PCR master mix (New England BioLabs, Genesearch Australia) and digesting original vectors with Dpn1 (New England BioLabs). pENTRYBRIcds or pENTRYBRIflns was used as template and in each case mutagenesis primers were designed through http://www.genomics.agilent.c om/primerDesignProgram.jsp. The individual pENTRYBRIcds and pENTRYBRIflns mutant constructs were generated using the appropriate forward and reverse oligonucleotides listed in Table S1 . Each plasmid was verified through sequencing. The BRI1 cytoplasmic domain from each of pENTRYBRIcds, pENTRYBRIcdsY956F, pENTRYBRIcdsG989I, pENTRYBRIcdsG1073K and pENTRYBRIcdsKR1083/4AA was independently recombined into pDEST17 to create pDEST17BRI1cds, pDEST17BRI1cdsY956F, pDEST17BRI1cdsG989I, pDEST17BRI1cdsG1073K and pDEST17-BRI1cdsKR1083/4AA respectively and verified by sequencing. The full-length BRI1 encoding region from each of pENTRYBRIflns, pENTRYBRIflnsY956F and pENTRYBRIflnsKR1083/4AA were independently recombined into pEarleyGate103 (Earley et al., 2006) to create pEarleyGate103BRI1flns, pEarleyGate103BRI1flnsY956F and pEarleyGate103BRI1flnsKR1083/4AA, respectively.
Recombinant protein preparation
For the expression of BRI1 , BRI1 Y956F, BRI1 G989I, BRI1 G1073K and BRI1 KR1083/4AA recombinant proteins the appropriate construct was transformed into One Shot BL21 (DE3)pLysS E. coli cells (Life Technologies, Carlsbad, CA, USA) and several independent colonies of each construct were selected, induced by adding 0.2% arabinose then grown for a further 3 h at 37°C (Muleya et al., 2013) . The recombinant BSK1 BRI1 BAK1 P P P P P P P P P P P P P cGMP GTP P P P P Transcription P BZR1/2 14-3-3 proteins were purified under native conditions as described in Protocols 9 and 12 of the QIAexpressionist manual (Qiagen).
Tobacco leaves and immunoprecipitation
For the expression of BRI1 KR1083/4AA proteins in tobacco the appropriate construct was transformed into Agrobacterium tumefaciens strain GV3101 (pMP90). A. tumefaciens mediated transient expression experiments (method adapted from (Thatcher et al., 2016) were performed on 4-5 weeks old Nicotiana benthamiana plants grown at 22°C under a 16-h-light/8-h-dark photoperiod. A. tumefaciens strains grown in 2YT media where harvested by centrifugation and resuspended in infiltration media (10 mM MES pH 5.6; 10 mM MgCl 2 ; 150 lM acetosyringone) to a final OD 600 of 0.5 and incubated at room temperature for 3 h. Immediately prior to infiltration, each strain was diluted in infiltration media to OD 600 of 0.2 and infiltrated into the underside of tobacco leaves using a needleless syringe. Leaves were harvested after 2 days. Infiltrated regions were weighed, ground under liquid nitrogen and extracted in 1 ml extraction buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1% v/v Igepal) with 1 mM PMSF per gram of leaf tissue. Tissue was defrosted at 4°C on a rotating wheel with manual shaking every 2 min over a period of 10 min, and centrifuged at 4°C for 10 min at 2300 g before transferring the supernatant to a new tube and repeating the centrifugation step. Supernatant was immediately used in immunoprecipitation experiment or stored at À80°C until required . GFP-Trap (ChromoTek, Aachen, Germany) was used to immunoprecipitate the full-length proteins as described by (Thatcher et al., 2016) . Isolation of full-length proteins was confirmed by immunoblot analysis probing with rabbit anti-GFP primary antibody (Thermo Fisher Scientific, San Jose, CA, USA) and goat-anti-rabbit IRDye 800CW (Li-Cor Biosciences, Millenium Science, Mulgrave, VIC, Australia) to detect GFP using the Odyssey infrared imaging system (Li-Cor Biosciences).
Assessment of GC activity
GC activity in vitro was assessed by measuring cGMP generated from GTP in the presence of 5 lg purified protein as previously described (Kwezi et al., 2007) using the cGMP enzyme immunoassay (EIA) Biotrak System (GE Healthcare, USA) with the acetylation protocol as described in the supplier's manual or by mass spectrometry. Mass spectrometry detection and quantitation of cGMP were done on a Thermo LTQ Velos Orbitrap mass spectrometer (Thermo Fisher Scientific) that is equipped with a heated ESI ion source. The ionization source parameters were optimized in positive ESI mode using pure cGMP (Sigma, St Louis, MO, USA) dissolved in HPLC-grade water. The LC-MS/MS analysis was performed by injecting 10 ll of standard or sample onto a Sepax SFC-Cyano column (4.6 mm 9 150 mm, 5 lm) (Sepax Technologies, Newark, DE, USA) and eluting in isocratic mode using a solvent mix of 10 mM ammonium acetate in 40/60 acetone nitrile/ water for 5 min and at a mobile phase flow rate of 0.5 ml/min. All analyses were carried out in positive ionization mode using a metal needle with a spray voltage of 4 kV. The source vaporizing temperature and the ion transfer tube temperature were set at 310°C and 260°C, respectively. Instrument control and data analysis were performed using the Xcalibur software (Thermo Scientific, USA).
In vitro kinase assays
Kinase activity of the cytoplasmic domain of wild-type BRI1 was measured as an increase in fluorescence of the phosphorylated Sox substrate peptide (Shults and Imperiali, 2003) (Kwezi et al., 2011) . Kinase activity of wild-type and mutant recombinant proteins was compared using the peptide BR13 (Oh et al., 2000) as a substrate. In brief, recombinant protein and BR13 as substrate were incubated together in buffer (50 mM HEPES pH7.5, 10 mM MgCl 2, 0.2 mM CaCl, 0.1 mg ml À1 peptide substrate, 1 lg ml À1 recombinant protein) with or without 5 mM ATP for 20 min and terminated by adding 75 mM H 3 PO 4 . The reactions containing the BR13 peptide were spotted onto nitrocellulose over a heat block set at 50°C to dry and probed with Pro-Q phosphoprotein blot stain (Thermo Fisher Scientific) and visualized with a Typhoon Trio variable imager (GE Healthcare, Buckinghamshire, UK) using a 488 nm blue laser and a 520 nm band-pass (BP) 40 emission filter. Reactions containing full-length immunoprecipitated proteins and full-length myelin basic protein (MBP) were undertaken in reaction as above and separated on 10% SDS-PAGE before staining with Pro-Q-Diamond phosphoprotein gel stain (Thermo Fisher Scientific). Phosphoprotein bands were visualized in a Typhoon Trio variable imager. Image intensities were quantified using FIJI software (http://imagej. net/Fiji/Downloads; accessed 2 June 2016) and normalised against phosphoprotein standard.
cGMP-induced phosphoproteins
Cells derived from roots of Arabidopsis thaliana (ecotype Columbia-0) were grown with either light ( 14 N) or heavy ( 15 N) potassium nitrate on a shaking platform (120 rpm) in Gamborg's B-5 basal salt mixture (Sigma-Aldrich) supplemented with 2,4-dichlorophenoxyacetic acid (0.5 lg ml
À1
) and kinetin (0.05 lg ml
) in a growth chamber (Innova â 43, New Brunswick Scientific Co., NJ, USA) at 23°C under 12 h light/dark cycles as previously described (Turek et al., 2014) . The cell cultures were treated with 100 nM cGMP or with water (control) for 5 min. Proteins were extracted, digested and fractionated as previously described (Groen et al., 2013) . Phosphopeptide enrichment was undertaken as previously described (Zhang et al., 2013) . Enriched phosphopeptides were analysed on a Q-Exactive Orbitrap with nano-electrospray ionization (Thermo Fisher Scientific) coupled to a nanoLC Dionex Ultimate 3000 UHPLC (Thermo Fisher Scientific). Samples were trapped on a 180 lm 9 20 mm, C18, 5 lm, 100 A trapping column Acclaim PepMap 100 (Thermo Fisher Scientific) with the ll PickUp Injection mode using the loading pump at 15 ll min À1 flow rate for 3 min. Samples were then loaded on a RSLC, 75 lm 9 500 mm, nanoViper, C18, 2 lm, 100 A column (Acclaim, PepMap) retrofitted to an EASY-spray source with a flow rate of 300 nl min À1 (buffer A: HPLC-grade H 2 O, 0.1% (v/v) formic acid; buffer B: 100% (v/v) ACN, 0.1% (v/v) formic acid). Peptides were eluted over a 60 min gradient (0-3 min: 2% buffer B, 3-30 min: 5 to >40% buffer B, 30-35 min: 95% buffer B, 35-60 min: 2% buffer B). Peptides were transferred to the gaseous phase with positive ion electrospray ionization at 1.8 kV. Top 20 precursors were acquired between 380 and 1600 m/z with a 1.5 precursor ion selection window, a dynamic exclusion of 20 sec, a normalised collision energy (NCE) of 25 and a resolution of 70 000 in MS1 and 17 500 in MS2. Data were recorded using Χcalibur TM software version 2.1 (Thermo Fisher Scientific) and files were converted from '.raw' to '.mzXML' using MSConvert and then '.mzXML' files to '.mgf' using iSPY (Gutteridge et al., 2010) . The.mgf files were then finally imported into MASCOT (Matrix Science, London, UK), with carbamidomethyl as a fixed modification, and oxidation on methionine (M) residues and phosphorylation on serine (S), threonine (T), and tyrosine (Y) residues as variable modifications; 25 ppm of peptide tolerance, 0.8 Da of MS/MS tolerance; a maximum of two missed cleavages, a peptide charges of +2, +3, or +4; and selection of decoy database. Mascot '.dat' output files were imported into iSPY for 14 N/ 15 N quantitation and analysed through percolator for improved identification (Brosch et al., 2009) . The 14 N and 15 N peptide isotopic peaks from MS1 dataset were used to compare the theoretical mass difference between the heavy and light peptides, and the typical isotopic distribution patterns. After normalisation, only peptides detected in at least two biological replicates, with a fold change |AE1.5| and a P ≤ 0.05 were considered for further analysis. ) and the mutants: BRI1 G1073E, BRI1 G1073K, BRI1 Y956F and BRI1 G989I were modelled against the crystal structure of the BRI1 kinase domain (PDB entry: 4OA2; Bojar et al., 2014) using Modeller (ver. 9.14) (Sali and Blundell, 1993) . GTP docking simulation was performed using AutoDock Vina (ver. 1.1.2) (Trott and Olson, 2010) . All structures and images were analysed and prepared with UCSF Chimera (Pettersen et al., 2004) and PyMOL (ver. 1.7.4) (The PyMOL Molecular Graphics System, Schr€ odinger, LLC, Cambridge, MA, USA).
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